Oral Anticoagulants Versus Antiplatelet Therapy for Preventing Further Vascular Events After Transient Ischemic Attack or Minor Stroke of Presumed Arterial Origin

A. Algra, MD; E.L.L.M. De Schryver, MD; J. van Gijn, MD, FRCP, FRCPE; L.J. Kappelle, MD; P.J. Koudstaal, MD

Background
Patients who are entered in clinical trials after a transient ischemic attack or nondisabling ischemic stroke have an annual risk of important vascular events (death from all vascular causes, nonfatal stroke, or nonfatal myocardial infarction) of between 4% and 11%.1,2 Aspirin, in a daily dose of 30 mg or more, offers only modest protection after cerebral ischemia: it reduces the incidence of major vascular events by 20% at most.1,3 Secondary prevention trials after myocardial infarction indicate that treatment with oral anticoagulants is associated with a risk reduction approximately twice that of treatment with antiplatelet therapy.1,4–7

Objectives
This review aimed to (1) compare the efficacy of oral anticoagulants and antiplatelet therapy in the secondary prevention of vascular events after cerebral ischemia of presumed arterial origin and (2) compare the safety of oral anticoagulants and antiplatelet therapy in the secondary prevention of vascular events after cerebral ischemia of presumed arterial origin.

Search Strategy
This review draws on the search strategy developed for the Cochrane Stroke Review Group as a whole. Relevant trials were identified in the Specialized Register of Controlled Trials. Authors of published trials were contacted for further information and unpublished data.

Selection Criteria
Randomized trials with concealed treatment allocation on long-term (>6 months) secondary prevention after recent (<6 months) transient ischemic attack or minor ischemic stroke of presumed arterial origin were selected. The oral anticoagulant therapy was to be of specified intensity (by means of the International Normalized Ratio [INR]) with warfarin, phenprocoumon, or acenocoumarol versus a single antiplatelet drug (or combination of antiplatelet agents).

Data Collection and Analysis
Two reviewers selected trials meeting the inclusion criteria and extracted details of randomization methods, blinding of treatments and assessments, whether intention-to-treat analysis is possible from the published data, whether treatment groups are comparable with regard to major prognostic risk factors for outcomes, the number of patients who are excluded or lost to follow-up, definition of outcomes, and entry and exclusion criteria. The method-
intense anticoagulation (INR 3.0 to 4.5) is not safe and should not be used in this setting. Low-intensity anticoagulation (INR 1.4 to 2.8) is not likely to be more efficacious than aspirin.

Note: Cochrane Reviews are regularly updated as new information becomes available and in response to comments and criticisms. Readers should consult The Cochrane Library for the latest version of a Cochrane Review. Information on The Cochrane Library can be found at www.update-software.com.

References

Key Words: anticoagulants • antiplatelet therapy • cerebral ischemia • randomized controlled trials